As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn explores pharma's priorities on pricing, profits and progress post-
The FDA "has failed in its responsibility to protect patients and families from unproven treatments with known harms" in approving Biogen's Alzheimer's disease drug Aduhelm.
Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs.
Unless president Donald Trump is successful with legal challenges, Democratic rival Joe Biden looks to have won the White House in last week’s election but faces the challenges of a divided
Pharma may have avoided a worst case scenario amid the political upheavals in the US elections with the threat of tough drug price legislation lowered, with hawkish Democrats unlikely to wi
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.